Key Players
Competitive Landscape
Marketed oral products and development-stage medicines are creating different competition in oral GLP-1 receptor agonist market. Novo Nordisk and Eli Lilly compete through approved tablets, dose instructions, pharmacy supply and direct channels. AstraZeneca, Structure Therapeutics, Viking Therapeutics, Roche and Kailera compete through clinical results and progress towards registration. Pfizer discontinued danuglipron after safety concern developed, which shows that oral administration alone cannot support a medicine programme. Product approval, available strengths, clinical outcome and reimbursement is expected to remain major competition factors.
Confirmatory studies and development of peptide and small-molecule tablets are becoming major competitive activities. AstraZeneca advanced elecoglipron into Phase III in June 2026 after reporting 11.8% weight loss at 36 weeks. Movement into Phase III may add another once-daily oral medicine if the programme receives authorization. Pfizer discontinued danuglipron in April 2025 after reviewing a potential drug-induced liver injury case, due to which the candidate was removed from development.[19] Efficacy along with tolerability is expected to shape competition in oral GLP-1 receptor agonist market.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| June 2026: AstraZeneca advanced elecoglipron into Phase III after reporting 11.8% weight loss at 36 weeks. | Increasing demand for effective once-daily oral treatment. | Small-molecule tablets are entering confirmatory studies. | A food-flexible oral option may develop if later trials supports authorization. |
| August 2025: Viking reported up to 12.2% mean weight loss after 13 weeks with oral VK2735. | Increasing interest in oral GLP-1 and GIP activity. | Peptide multiagonists are being tested as tablets. | A differentiated maintenance or weight-loss regimen after later-stage validation. |
| April 2025: Pfizer discontinued danuglipron after reviewing a potential drug-induced liver injury case. | Safety evidence affects continuation of oral medicine programmes. | Developers are reducing oral programmes after safety and tolerability review. | Investment can move towards oral candidates having clearer safety and efficacy evidence. |
Novo Nordisk and Eli Lilly operates commercial oral GLP-1 franchises through pharmacy and direct-access channels. AstraZeneca, Structure Therapeutics, Viking Therapeutics, Roche and Kailera differs by molecule design, trial stage and available human evidence. Pfizer remains active in metabolic research, but danuglipron oral programme has been discontinued.
Source: Future Market Insights, Oral GLP-1 Receptor Agonist Market Report, 2026-2036.
Public evidence does not establish one verified market-share leader in oral GLP-1 receptor agonist market. Novo Nordisk and Eli Lilly have authorized oral products, whereas other prominent companies are advancing clinical-stage medicines.
Who leads the oral GLP-1 receptor agonist market?
Novo Nordisk and Eli Lilly are among the leading commercial participants owing to authorized oral products and established supply channels. However, public evidence does not provide one verified market-share leader across the complete oral GLP-1 receptor agonist market.
What should buyers evaluate before approving an oral GLP-1 medicine?
Buyers evaluates approved indication, clinical outcome, contraindications, tablet strengths, administration instructions, reimbursement and supply availability before adding an oral GLP-1 medicine. Difference in dose and food instruction means that oral products cannot be treated as automatically interchangeable.
Which companies have documented later-stage oral programmes?
AstraZeneca moved elecoglipron into Phase III, whereas Structure Therapeutics began the Phase 3 ACCOMPLISH programme for aleniglipron. Viking completed Phase 2 testing of oral VK2735 and Kailera continues oral multiagonist development. Progress of these programmes is expected to increase later-stage product competition.
Which companies provide marketed oral products through multiple access routes?
Novo Nordisk and Eli Lilly supplies marketed oral products through pharmacy or direct-access channels. Geographic availability depends on national authorization and does not automatically transfer from one country to another.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Novo Nordisk | Commercial oral semaglutide products | Wegovy tablets are authorized for weight management in the USA and UK. |
| Eli Lilly and Company | Commercial small-molecule oral products | Foundayo received U.S. approval in April 2026 and entered retail, telehealth, and direct channels. |
| AstraZeneca plc | Late-stage oral medicine developer | Elecoglipron moved into Phase III after VISTA and SOLSTICE Phase IIb results in June 2026. |
| Structure Therapeutics Inc. | Late-stage oral medicine developer | Aleniglipron entered the Phase 3 ACCOMPLISH programme during 2026. |
| Viking Therapeutics, Inc. | Oral multiagonist developer | Oral VK2735 completed Phase 2 testing with results reported in August 2025. |
| Roche Holding AG | Clinical-stage oral medicine developer | CT-996 has documented human clinical development for obesity. |
| Kailera Therapeutics, Inc. | Oral multiagonist developer | Ribupatide and KAI-7535 support oral obesity development activity. |
| Pfizer Inc. | Discontinued oral medicine programme | Danuglipron development ended in April 2025 after a safety review. |
Research Methodology
The assessment covers verified oral products and clinical programmes, while segment forecasts remain report estimates rather than published company shares. Companies are assessed on the basis of available function, intended use, current product activity and geographic availability. The ratings describe publicly documented capability and do not represent company revenue or global market share.
